Log in to your Inderes Free account to see all free content on this page.
Create account

Orion

73.35 EUR

-0.14 %

14,375 following

ORNBV

NASDAQ Helsinki

Biotechnology & Pharmaceuticals

Health Care

-0.14 %
+6.46 %
+6.85 %
+15.24 %
+8.83 %
+49.45 %
+58.94 %
+103.41 %
+553.16 %

Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.

Read more
Market cap
10.35B EUR
Turnover
11.6M EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Buy
Target price
Updated
01.04.2026
Antti Siltanen
Antti Siltanen

Analyst

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
23.4.
2026

Interim report Q1'26

17.7.
2026

Interim report Q2'26

19.10.
2026

Half year dividend

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
And then potentially destroy Orion’s shareholder value in the process. As an Orion shareholder (I don’t own Faron), I do not support such a scenario at all. Deals can be made for interesting drug candidates, if there is potential. On the other hand, if Faron’s performance continues...
2/16/2026, 5:45 PM
by L Dabio
17
Something for a small group of patients, and another step forward as well: orionpharma.com Orion Pharman ODM-212-molekyyli on saanut FDA:n harvinaislääkestatuksen... ORION OYJ LEHDISTÖTIEDOTE 20.4.2026 KLO 16.00
4/20/2026, 2:10 PM
by PörssiPatruuna
14
Antti has made a new company report on Orion We raise our earnings estimates for Orion based on the outlook for Nubeqa, the company’s key earnings growth driver. Bayer, responsible for the sales and marketing of the best-in-class (AR inhibitor) prostate cancer drug, recently provided...
4/1/2026, 5:08 AM
by Sijoittaja-alokas
13
Turku-based Thestra finds a partner in Orion to support its unique invention Despite decades of research, there have been no targeted treatments for head and neck cancer. A medical startup has invented a method that ensures an accurate diagnosis of the cancer. ts.fi – 17 Feb 26 Turkulainen...
2/18/2026, 8:28 AM
by Dissidentti
13
Here are Antti’s comments on an unsurprising Q4 Orion’s Q4 report and the full financial year were strong, even though the end of the year fell slightly short of market expectations. The quarter was characterized by a 180 MEUR milestone payment, adjusted for which the result improved...
2/13/2026, 6:13 AM
by Sijoittaja-alokas
10
Considering the precarious situation Faron has found itself in, perhaps the possibility of merging it with Orion should be seriously explored. Although Orion might not yet be considered a true Big Pharma (BP) company, a merger with Faron would not be an overwhelming risk for it. ...
2/16/2026, 2:35 PM
by Tero Vierros
8
https://www.marketscreener.com/news/danske-bank-upgrades-orion-to-buy-hold-sets-price-target-at-75-euros-bn-ce7e5fdede8af721
3/10/2026, 9:16 AM
by Dissidentti
7
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.